Commerzbank Maintains Their Hold Rating on Fresenius Medical Care Corp (FMS)
Commerzbank analyst Oliver Metzger maintained a Hold rating on Fresenius Medical Care Corp (FMS) yesterday and set a price target of $54. The company’s shares closed yesterday at $41.31.
The word on The Street in general, suggests a Hold analyst consensus rating for Fresenius Medical Care Corp with a $42 average price target, a 1.7% upside from current levels. In a report issued on May 6, RBC Capital also maintained a Hold rating on the stock with a $42 price target.
See today’s analyst top recommended stocks >>
Based on Fresenius Medical Care Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $485 million. In comparison, last year the company had a net profit of $342 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.